About James La Rossa

This author has not yet filled in any details.
So far James La Rossa has created 124 blog entries.

Study Links Increased Risk of Mental Disorders with Childhood Infections

By |2018-12-06T11:40:55+00:00December 6th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Furthering the role of immune system disorders in the development of mental disorders, recent research links infections that children contract during their childhood with increased risk of mental disorders during childhood and adolescence. The first study of its kind shows that high temperatures, sore throats and infections during childhood can [...]

Impact Of Gabapentin Adjunct Use With Benzodiazepines For The Treatment Of Alcohol Withdrawal In A Psychiatric Hospital

By |2018-11-21T11:30:26+00:00November 21st, 2018|Articles In Press|

ORIGINAL RESEARCH Vadiei, N., Smith T. L., Walton, A. E., and Kjome, K. L. Abstract Introduction: Benzodiazepines are currently the gold standard for treatment of alcohol withdrawal. Gabapentin has growing evidence to support its use in the treatment of alcohol use disorder, however there is limited evidence regarding its role in [...]

Paroxetine Versus Vortioxetine For Depressive Symptoms In Postmenopausal Transition: A Preliminary Study

By |2018-11-21T11:30:38+00:00November 21st, 2018|Articles In Press|

EVIDENCE-BASED MEDICINE Callegari C, Ielmini M., Caselli I., Lucca G., Isella C., Diurni M., Pettenon F., and Poloni N. Abstract Background: The impact of menopause is a consequence of social, physical and mental changes; hormonal changes play an important role in inducing an increased risk of developing depressive symptoms. It is [...]

An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome

By |2018-11-21T11:31:54+00:00November 21st, 2018|Articles In Press|

COMPLICATED CASE HISTORIES By Roland van Rensburg and Eric H. Decloedt Abstract Neuroleptic malignant syndrome is a rare, idiosyncratic emergency associated with exposure to dopamine antagonists, commonly antipsychotic drugs. The typical clinical picture consists of altered consciousness, muscular rigidity, fever, and autonomic instability. While the condition has generally been well described, the [...]

Akathisia Induced by Abrupt Withdrawal of Risperidone: A Case Report

By |2018-11-21T11:32:20+00:00November 21st, 2018|Articles In Press|

COMPLICATED CASE HISTORIES By Gangaparameswari Soundarrajan, Bharti Chogtu Magazine, Vybhav Krishna, Avinash Kamath G, and Manisha murugesan Abstract Akathisia is a common movement disorder that occurs as a consequence of antipsychotic therapy. However, its occurrence secondary to risperidone withdrawal has been reported rarely. Reporting of such rare adverse event gains profound importance because changing the [...]

Exercise as a Treatment for Schizophrenia: a Review

By |2018-11-21T11:32:34+00:00November 21st, 2018|Articles In Press|

GENERAL PSYCHIATRY By Steven J. Girdler, Jamie E. Confino and Mary E. Woesner Abstract Schizophrenia is a mental disorder that is characterized by progressive cognitive impairment in areas of attention, working memory, and executive functioning. Although no clear etiology of schizophrenia has been discovered, many factors have been identified that contribute to [...]

Promoting The Discussion Of The Beneficial Effects Of Ketamine To Treat Refractory Depression

By |2018-11-21T11:32:49+00:00November 21st, 2018|Articles In Press|

BRIEF REPORT Priyanka, G. and Viswanath, O. Abstract We read a recent article published by CNN titled “Ketamine offers lifeline for people with severe depression, suicidal thoughts1” with great interest. The article traces the story of a man with a 35-year history of severe refractory depression, suicidal ideation, and recent suicide [...]

Cassipa Approved by FDA for Opioid Dependence

By |2018-09-12T15:28:07+00:00September 12th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

A new dosage strength of buprenorphine and naloxone sublingual film was approved recently by the Food and Drug Administration. Cassipa sublingual film, made by Teva Pharmaceuticals, is a 16 mg/4 mg dosage of buprenorphine and naloxone for the maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual film also is [...]

Seven-Year Analysis on Benzodiazepine Prescribing for Children, Adolescents, and Young Adults Showed Marked Increase

By |2018-08-09T08:01:59+00:00August 9th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Conclusions The overall increase in prevalence rates of BZD dispensations during the study period and the unexpectedly high proportion of individuals who were prescribed a BZD on a long-term basis at a young age indicate a lack of congruence with international and national guidelines. These findings highlight the need for [...]